Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of WNT974 + LGX818 + cetuximab in BRAF V600-mutant, KRAS wild-type metastatic colorectal cancer with Wnt pathway alterations
NL-OMON45070Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WNT974, encorafenib and cetuximab in colorectal cancer (CRC), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities and Overall response rate. Started Dec 2014; status: recruiting.
02
Drugs
WNT974encorafenibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON45070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45070.